Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B)

Next Previous
Trial Profile

Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms NEWBEAT

Most Recent Events

  • 07 Dec 2022 Status changed from active, no longer recruiting to completed.
  • 18 Jun 2022 Primary endpoint(Overall response rate) has been met, according to the results published in the European Journal of Cancer.
  • 18 Jun 2022 Primary results(WJOG9917B) and biomarker analysis(WJOG9917BTR) published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top